Compared side by side
Survodutide vs efinopegdutide: how they differ
The short answer
Both are weekly GLP-1 and glucagon dual agonists that act on the liver as well as on weight: survodutide, from Boehringer Ingelheim, fully activates the GLP-1 receptor and partly the glucagon receptor, and efinopegdutide, now with Merck, is tuned about 2 to 1 toward GLP-1 and developed for MASH, the inflamed form of fatty liver disease. Neither is approved; survodutide’s phase 3 results were published in 2026. Survodutide averaged 12–13% weight loss at 76 weeks counting everyone, and most people in its liver trial cut their liver fat by at least 30%; in efinopegdutide’s 52-week phase 2b trial, about 6 in 10 people had their liver inflammation resolve on biopsy, against about 1 in 8 on placebo.
Side by side
| Compared | Survodutide | Efinopegdutide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | BI 456906, BI456906, Survo | MK-6024, JNJ-64565111, Efino |
| What it is | A weekly shot that activates two receptors: GLP-1, for appetite and blood sugar, and glucagon, which clears fat from the liver and, in mice, raises energy use. | A once-weekly GLP-1 and glucagon dual agonist that Merck is developing for MASH, the inflamed form of fatty liver disease. |
| How it works | Glucagon and GLP-1 receptor dual agonist: a 29-amino-acid peptide built on the glucagon sequence, carrying a C18 fatty acid that binds albumin for once-weekly dosing. It fully activates the GLP-1 receptor (appetite, insulin) and partly activates the glucagon receptor, which raises energy expenditure (shown in mice) and draws down liver fat (the liver-fat drop is measured in people). Developed by Boehringer Ingelheim with Zealand Pharma; its phase 3 (SYNCHRONIZE) results were published in 2026, and it is not approved. | Once-weekly GLP-1 and glucagon receptor co-agonist, the same pair as mazdutide and survodutide, tuned about 2 to 1 toward GLP-1. GLP-1 lowers appetite and weight; glucagon acts on the liver directly and is thought to make it burn more of its stored fat. That is why Merck is developing it for MASH, the inflamed form of fatty liver disease, rather than for weight alone. Investigational; first made by Hanmi Pharmaceutical, then tested by Janssen in obesity, and now with Merck. |
| Commonly reported | Less appetite and early fullness, with nausea or vomiting during the long dose climb and a resting heart rate a few beats higher. Average weight loss at 76 weeks was 12–13% counting everyone and up to 16.6% for people who stayed on it, and most people in its liver trial cut their liver fat by at least 30%. | GI side effects during step-ups, and weight loss too. Not approved anywhere. |
| Studied range | Research range: 0.3–6 mg, starting dose 0.3 mg. Studied in research — not a recommendation. | Research range: 4–10 mg, starting dose 2 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | Long enough for once-weekly dosing: a fatty-acid chain binds it to albumin; phase I measured it in people (Jungnik 2023), but the figure is not in the trial summaries | Not reported in an open human PK source; dosed once weekly in all its trials |
| Route | SubQ injection | SubQ injection |
| Typical run | Phase 3 trials run it continuously for 76 weeks after a slow climb of about 24 weeks. Not approved; Boehringer Ingelheim expects its cardiovascular outcomes trial to report later in 2026. | Used continuously, once weekly, in its trials: 24 to 52 weeks, stepping up every 4 weeks from 2 mg in the MASH trial. No trial has tested stopping it. |
| Evidence | Established: clinical trials or FDA-approved use exists | Moderate: animal studies + some human data |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, higher resting heart rate | Nausea, vomiting, diarrhea |
- Category
- SurvodutideMetabolic & GLP-1
- EfinopegdutideMetabolic & GLP-1
- Also known as
- SurvodutideBI 456906, BI456906, Survo
- EfinopegdutideMK-6024, JNJ-64565111, Efino
- What it is
- SurvodutideA weekly shot that activates two receptors: GLP-1, for appetite and blood sugar, and glucagon, which clears fat from the liver and, in mice, raises energy use.
- EfinopegdutideA once-weekly GLP-1 and glucagon dual agonist that Merck is developing for MASH, the inflamed form of fatty liver disease.
- How it works
- SurvodutideGlucagon and GLP-1 receptor dual agonist: a 29-amino-acid peptide built on the glucagon sequence, carrying a C18 fatty acid that binds albumin for once-weekly dosing. It fully activates the GLP-1 receptor (appetite, insulin) and partly activates the glucagon receptor, which raises energy expenditure (shown in mice) and draws down liver fat (the liver-fat drop is measured in people). Developed by Boehringer Ingelheim with Zealand Pharma; its phase 3 (SYNCHRONIZE) results were published in 2026, and it is not approved.
- EfinopegdutideOnce-weekly GLP-1 and glucagon receptor co-agonist, the same pair as mazdutide and survodutide, tuned about 2 to 1 toward GLP-1. GLP-1 lowers appetite and weight; glucagon acts on the liver directly and is thought to make it burn more of its stored fat. That is why Merck is developing it for MASH, the inflamed form of fatty liver disease, rather than for weight alone. Investigational; first made by Hanmi Pharmaceutical, then tested by Janssen in obesity, and now with Merck.
- Commonly reported
- SurvodutideLess appetite and early fullness, with nausea or vomiting during the long dose climb and a resting heart rate a few beats higher. Average weight loss at 76 weeks was 12–13% counting everyone and up to 16.6% for people who stayed on it, and most people in its liver trial cut their liver fat by at least 30%.
- EfinopegdutideGI side effects during step-ups, and weight loss too. Not approved anywhere.
- Studied range
- SurvodutideResearch range: 0.3–6 mg, starting dose 0.3 mg. Studied in research — not a recommendation.
- EfinopegdutideResearch range: 4–10 mg, starting dose 2 mg. Studied in research — not a recommendation.
- How often
- SurvodutideWeekly
- EfinopegdutideWeekly
- Half-life
- SurvodutideLong enough for once-weekly dosing: a fatty-acid chain binds it to albumin; phase I measured it in people (Jungnik 2023), but the figure is not in the trial summaries
- EfinopegdutideNot reported in an open human PK source; dosed once weekly in all its trials
- Route
- SurvodutideSubQ injection
- EfinopegdutideSubQ injection
- Typical run
- SurvodutidePhase 3 trials run it continuously for 76 weeks after a slow climb of about 24 weeks. Not approved; Boehringer Ingelheim expects its cardiovascular outcomes trial to report later in 2026.
- EfinopegdutideUsed continuously, once weekly, in its trials: 24 to 52 weeks, stepping up every 4 weeks from 2 mg in the MASH trial. No trial has tested stopping it.
- Evidence
- SurvodutideEstablished: clinical trials or FDA-approved use exists
- EfinopegdutideModerate: animal studies + some human data
- Common side effects
- SurvodutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, higher resting heart rate
- EfinopegdutideNausea, vomiting, diarrhea
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Survodutide
- Day 1–14 · 0.3 mg The 0.3 mg start
- Day 15–168 The slow climb
- Day 99+ · 3.6 mg 3.6 mg, the lower phase 3 dose
- Day 141+ · 6 mg 6.0 mg, the top phase 3 dose
- Day 169–336 Liver fat: where the glucagon arm shows
Efinopegdutide
- Day 1–28 · 2 mg A gentle first month
- Day 29–364 · 4 mg Four milligrams
- Day 57–364 · 7 mg The dose the trial favoured
- Day 57–364 Weight comes down too
- Day 85–364 · 10 mg Ten milligrams: more side effects, not more benefit
Questions people ask
How long do survodutide and efinopegdutide last?
The half-life of survodutide is long enough for once-weekly dosing: a fatty-acid chain binds it to albumin; phase I measured it in people (Jungnik 2023), but the figure is not in the trial summaries. The half-life of efinopegdutide is not reported in an open human PK source; dosed once weekly in all its trials.
How often are survodutide and efinopegdutide taken?
Survodutide: weekly. Route: SubQ injection. Efinopegdutide: weekly. Route: SubQ injection.
How are survodutide and efinopegdutide dosed in research?
The research range for survodutide is 0.3–6 mg, with a 0.3 mg starting dose. The research range for efinopegdutide is 4–10 mg, with a 2 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of survodutide and efinopegdutide?
For survodutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, higher resting heart rate. For efinopegdutide: nausea, vomiting, diarrhea.